CoLucid Pharmaceuticals is developing oral lasmiditan for the acute treatment of migraine and an intravenous formulation for use by health care professionals. The company has completed six clinical studies, including a Phase 2b trial treating a single migraine attack in 391 patients and a TQTc study. It plans to use the new funding to advance its Phase 3 program, including the first pivotal study COL MIG-301 “SAMURAI,” for acute migraine treatment. CoLucid emphasizes addressing unmet needs for patients poorly served by current therapies, including those with cardiovascular risk factors who may be unable to take triptans. The company is led by CEO Thomas P. Mathers and is partnered with ILDONG Pharmaceutical under a distribution and supply agreement for lasmiditan in South Korea and Southeast Asia. CoLucid is based in Durham, North Carolina. CoLucid Pharmaceuticals is a privately held biopharmaceutical company based in Research Triangle Park, NC, focused on developing therapies for migraine and other CNS disorders. Its lead program is lasmiditan, a Neurally Acting Anti‑Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of therapies. The company also lists COL-204 for wake promotion and a conjugated stigmine platform that has generated preclinical candidates for chronic pain, Alzheimer’s disease and psychiatric disorders. CoLucid intends to use the financing to advance lasmiditan into Phase 3 development and into pivotal studies planned for 2012. It is interacting with the FDA and is engaged in discussions with potential partners. As of the article, CoLucid has raised $7.5M of a planned $9.5M convertible note financing.

Total raised

$45M

Funding rounds

2

Latest round

Series C

Latest activity

Jan 2015